The Signal Transduction and Therapeutics Program Area is composed of 37 members, spanning 16 Departments within UCLA. In the past competing cycle, investigators from this Program authored 374 publications, of which 150 (40%) were inter-programmatic and 86 (23%) intra-programmatic. 143 (38%) were placed in high-impact journals. 27 members of this Program Area used 8 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled ~$16 million in total costs, including $3.6 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the STT Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the STT Program Area total $2,987,635. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twenty-four of the Program Area Members were the recipients of JCCC support. Since its inception in 1996, the Signal Transduction Program Area has been engaged in investigating both basic mechanisms of signal transduction in normal cells and alterations in signal transduction in tumor cells. During the current CCSG funding period, we have seen increased activity in translational research, with the long-term aim of bringing basic science findings to clinical application. A number of activities, including joint meetings with clinical Program Areas, culminated in the merger of the Signal Transduction Program Area with a portion of the membership of .Cancer Translational Therapeutics Program Area. This extended and enriched Program Area is now called the Signal Transduction and Therapeutics Program Area. These changes were also made in response to the 2002 CCSG review suggestions to place greater emphasis on translational research, and after extensive consultation with our External Advisory Board. The goals of our new Program Area are: (1) to characterize signaling pathways and identify novel signaling molecules;(2) to understand differences in signaling between cancer and normal cells;(3) to promote clinical trials with signaling inhibitors; and (4) to promote close cooperation between basic and clinical science. To facilitate these goals, we have instituted a number of Program Area activities. Specifically, we have organized three different seminar series. We continue with the "Signal Transduction and Therapeutics Research" seminars as well as seminars by outside speakers. In addition, we have a regularly scheduled "Signal Transduction and Therapeutics Program Area Lunch" for our members. Finally, we have initiated a new type of meeting: a "Signal Transduction and Therapeutics Round Table Discussion" to bring together basic scientists and clinicians.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications